Metformin protects against the principal inwardly rectifying potassium‐conducting channel (Kir4.1) in Müller cells; since, Bmal1 plays an intermediary role in the AMPK‐mediated increase in Kir4.1 protein expression, which makes Bmal1 supposed to be a potential therapeutic target to prevent Müller cell dysfunction in diabetic retinopathy (Alex et al., 2020). Here, BMAL1 is linked to diabetic retinopathy.